FIELD: organic chemistry, medicine, biochemistry.
SUBSTANCE: invention relates to 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazine-1-ylpyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidine-7-one isethionate salt and to its crystalline forms. These substances show properties of selective inhibitor of cyclin-dependent kinase 4 (CDK4) and can be used in treatment, for example, of inflammatory and cellular proliferative diseases. Crystalline forms of salt show powdery roentgenogram in values 2θ about 8.7, 13.5 and 17.6 (form A); 5.1, 11.8, 12.1, 12.8, 13.1 and 14.7 (form B), and 8.4, 8.9 and 21.9 (form D). Also, invention relates to methods for preparing crystalline 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazine-1-ylpyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidine-7-one isethionate salt, to medicinal agent and its using for preparing a medicinal agent.
EFFECT: valuable medicinal and biochemical properties of compound.
23 cl, 5 tbl, 18 dwg, 12 ex
Title | Year | Author | Number |
---|---|---|---|
SOLID FORMS OF SELECTIVE CDK4/6 INHIBITOR | 2014 |
|
RU2619944C2 |
PHARMACEUTICAL COMBINATIONS | 2014 |
|
RU2684106C2 |
COMBINATION INCLUDING CYCLIN-DEPENDENT KINASE 4 INHIBITOR OR CYCLIN-DEPENDENT KINASE 6 INHIBITOR (CDK4/6) AND mTOR INHIBITOR FOR TREATING CANCER | 2011 |
|
RU2589696C2 |
ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF PAH | 2020 |
|
RU2786588C1 |
COMBINATION THERAPY FOR TREATMENT OF MAMMARY GLAND CANCER | 2018 |
|
RU2764724C2 |
(1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-d]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE HYDROCHLORIDE | 2010 |
|
RU2562245C2 |
DERIVATIVES OF PYRIDOPYRIMIDINES, METHODS FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2002 |
|
RU2269527C2 |
HYDROXYLATED AND METHOXYLATED CYCLOPENTA[B]PYRIMIDINES AS PROTEIN KINASE INHIBITORS | 2007 |
|
RU2478632C2 |
CERTAIN PROTEIN KINASE INHIBITORS | 2015 |
|
RU2671494C2 |
NEW POLYMORPHS OF CALCIUM SALT AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATING AGENTS | 2019 |
|
RU2797511C2 |
Authors
Dates
2008-02-20—Published
2004-06-28—Filed